ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 949,04
0,71%
Dow Jones
44 565,07
0,00%
DAX
21 447,54
0,14%
Brent Oil
78,075
0,96%
Bitcoin
105 200,05
1,19%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Recursion Pharmaceuticals Inc (RXRX)

  7. Recursion Pharmaceuticals Inc (RXRX) Actualités

RXRX

Recursion Pharmaceuticals (RXRX)

Recursion Pharmaceuticals Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:RXRX
DateHeureSourceTitreSymboleSociété
17/01/202523h58PR Newswire (US)Healthcare AI Adoption Accelerates as Industry Eyes $125 Billion Growth by 2028NASDAQ:RXRXRecursion Pharmaceuticals Inc
17/01/202523h09Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
13/01/202523h26Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
13/01/202515h04Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RXRXRecursion Pharmaceuticals Inc
07/01/202515h15GlobeNewswire Inc.Recursion Announces Two Key Investigational Oncology Drugs Advancing to Clinical Trials, Targeting High Unmet Needs in Hematologic Malignancies, Small-Cell Lung Cancer, & MoreNASDAQ:RXRXRecursion Pharmaceuticals Inc
06/01/202514h30GlobeNewswire Inc.Recursion to Present at 43rd Annual JP Morgan Healthcare ConferenceNASDAQ:RXRXRecursion Pharmaceuticals Inc
20/12/202422h05GlobeNewswire Inc.Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing RulesNASDAQ:RXRXRecursion Pharmaceuticals Inc
17/12/202423h05Edgar (US Regulatory)Form 424B7 - Prospectus [Rule 424(b)(7)]NASDAQ:RXRXRecursion Pharmaceuticals Inc
10/12/202400h00GlobeNewswire Inc.Recursion Reports Interim Phase 1 Clinical Data for REC-617 Monotherapy, a Potential Best-in-Class CDK7 Inhibitor, With Encouraging Patient Response and Favorable TolerabilityNASDAQ:RXRXRecursion Pharmaceuticals Inc
03/12/202414h30GlobeNewswire Inc.Recursion announces first patient dosed in Phase 1/2 clinical study of REC-1245, a potential first-in-class, RBM39 degrader for Biomarker-Enriched Solid Tumors and LymphomaNASDAQ:RXRXRecursion Pharmaceuticals Inc
03/12/202401h02Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
27/11/202422h09Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:RXRXRecursion Pharmaceuticals Inc
20/11/202413h11Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:RXRXRecursion Pharmaceuticals Inc
20/11/202413h00GlobeNewswire Inc.Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discoveryNASDAQ:RXRXRecursion Pharmaceuticals Inc
13/11/202415h08GlobeNewswire Inc.Recursion and Exscientia Shareholders Approve the Proposed CombinationNASDAQ:RXRXRecursion Pharmaceuticals Inc
12/11/202422h54GlobeNewswire Inc.Recursion Announces the Release of OpenPhenom-S/16 in Google Cloud’s Model GardenNASDAQ:RXRXRecursion Pharmaceuticals Inc
08/11/202420h17Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:RXRXRecursion Pharmaceuticals Inc
06/11/202422h18Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:RXRXRecursion Pharmaceuticals Inc
06/11/202422h15GlobeNewswire Inc.Recursion Provides Business Updates and Reports Third Quarter 2024 Financial ResultsNASDAQ:RXRXRecursion Pharmaceuticals Inc
06/11/202412h12Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:RXRXRecursion Pharmaceuticals Inc
30/10/202413h22GlobeNewswire Inc.Recursion to Report Third Quarter 2024 Business Updates and Financial Results on November 6thNASDAQ:RXRXRecursion Pharmaceuticals Inc
22/10/202414h00GlobeNewswire Inc.Recursion announces first patient dosed in Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small molecule for recurrent Clostridioides difficile infectionNASDAQ:RXRXRecursion Pharmaceuticals Inc
10/10/202412h00Edgar (US Regulatory)Form DEFM14A - Definitive proxy statement relating to merger or acquisitionNASDAQ:RXRXRecursion Pharmaceuticals Inc
02/10/202414h00GlobeNewswire Inc.Recursion Announces FDA Clearance of Investigational New Drug Application for REC-1245, a Potential First-In-Class RBM39 Degrader for Biomarker-Enriched Solid Tumors and LymphomaNASDAQ:RXRXRecursion Pharmaceuticals Inc
17/09/202412h03Edgar (US Regulatory)Form PREM14A - Preliminary proxy statements relating to merger or acquisitionNASDAQ:RXRXRecursion Pharmaceuticals Inc
03/09/202414h00GlobeNewswire Inc.Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and TolerabilityNASDAQ:RXRXRecursion Pharmaceuticals Inc
09/08/202411h44IH Market NewsTSMC July Revenue Surges 45%, Nasdaq Accelerates Penny Stock Delistings, Moody’s Downgrades Intel to BAA1, and MoreNASDAQ:RXRXRecursion Pharmaceuticals Inc
08/08/202420h41GlobeNewswire Inc.CORRECTION - Recursion Provides Business Updates and Reports Second Quarter 2024 Financial ResultsNASDAQ:RXRXRecursion Pharmaceuticals Inc
08/08/202413h39GlobeNewswire Inc.Recursion and Exscientia Enter Definitive Agreement to Create a Global Technology-Enabled Drug Discovery Leader with End-to-End CapabilitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
08/08/202413h30GlobeNewswire Inc.Recursion Provides Business Updates and Reports Second Quarter 2024 Financial ResultsNASDAQ:RXRXRecursion Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:RXRX

Dernières Valeurs Consultées

BATSI
BUKACN
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2025 ADVFN PLC - Tous droits réservés